Eli Lilly Initiates Early Access Program for Promising Weight-Loss Drug, Retatrutide
Pharmaceutical titan, Eli Lilly, has announced the commencement of an expanded access program for its revolutionary experimental obesity drug, Retatrutide. This move will permit a select group of patients to avail the treatment prior to its official U.S. FDA approval.
The announcement, made on August 3, 2026, follows a report by STAT News that Lilly had previously granted compassionate use access to a single 79-year-old patient. This act led to a surge in requests from numerous physicians seeking the same for their patients.
Eligibility for this program requires patients to be 18 years or older, suffering from refractory obesity despite maximum approved obesity therapy, and exhibiting at least two serious or life-threatening obesity-related complications. Additionally, they must be unable to enroll in an ongoing clinical trial.
Retatrutide, a triple agonist, simultaneously targets three hormonal pathways — GLP-1, GIP, and glucagon. This makes it a more comprehensive solution than Lilly’s existing drug, Zepbound (a dual agonist), and Novo Nordisk’s Wegovy (a single agonist). In the clinical TRIUMPH trials, the highest 12 mg weekly dose resulted in an average weight loss of 28.3% over a span of 80 weeks. Lilly is set to file for FDA approval of Retatrutide in the first quarter of 2027.
The drug has sparked immense interest from the health and beauty sectors as a transformative weight management solution offering dramatic body composition results.
Source: Quartz – August 4, 2026